Effect of ten-valent pneumococcal conjugate vaccine introduction on pneumococcal carriage in Fiji: results from four annual cross-sectional carriage surveys

• Main Authors: Eileen M Dunne, PhD (Author), Catherine Satzke, PhD (Author), Felisita T Ratu, BPHN (Author), Eleanor F G Neal, MPH (Author), Laura K Boelsen, PhD (Author), Silivia Matanitobua, BLMS (Author), Casey L Pell, BBiomedSc (Author), Monica L Nation, BBiomedSc[Hons] (Author), Belinda D Ortika, MSc (Author), Rita Reyburn, MSc (Author), Kylie Jenkins, MPH (Author), Cattram Nguyen, PhD (Author), Katherine Gould, PhD (Author), Jason Hinds, PhD (Author), Lisi Tikoduadua, MBBS (Author), Joseph Kado, MMed (Author), Eric Rafai, MBBS (Author), Mike Kama, MBBS (Author), E Kim Mulholland, ProfMD (Author), Fiona M Russell, PhD (Author)
• Format: Book
• Published: Elsevier, 2018-12-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Summary: Background: The indirect effects of pneumococcal conjugate vaccines (PCVs) are mediated through reductions in carriage of vaccine serotypes. Data on PCVs in Asia and the Pacific are scarce. Fiji introduced the ten-valent PCV (PCV10) in 2012, with a schedule consisting of three priming doses...